PAND News
Archived Headlines
- Autoimmune disease biotech Pandion Therapeutics sets terms for $94 million IPO 07/13/20
- US IPO Week Ahead: GoHealth takes the lead in a 9 IPO Week 07/10/20
- US IPO Weekly Recap: Agora pops 153% while Albertsons falls flat in a 6 IPO week 06/26/20
- Autoimmune disease biotech Pandion Therapeutics files for a $75 million IPO 06/26/20
US IPO Week Ahead: The IPO market takes a breather in a 4 IPO week
Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
US IPO Weekly Recap: nCino pops 195% in 8 IPO week
Eight IPOs and six SPACs entered public markets this past week, led by nCino (NCNO), which ...read more
Autoimmune T cell biotech Pandion Therapeutics prices upsized IPO at $18 high end
Pandion Therapeutics, a Phase 1 biotech developing engineered T cells for autoimmune diseases, raised $135 million by offering a further upsized 7.5 million shares at $18, the high end of the $16 to $18 range. The company originally filed to offer 5.5...read more
Autoimmune disease biotech Pandion Therapeutics ups proposed share offering ahead of $119 million IPO
Pandion Therapeutics, a Phase 1 biotech developing engineered Treg cells for autoimmune diseases, increased the proposed share offering for its upcoming IPO on Thursday. The Watertown, MA-based company now plans to raise $119 million by offering 7 million...read more